Floatz logo

Olaparib

Paraganglioma/ Phaeochromocytoma

Fundación de investigación HMSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Paraganglioma/ Phaeochromocytoma cohort.

Asset / SponsorPhaseRating
Oxodotreotide
National Cancer Institute (NCI)
Phase 1/2CCC
FAPI74
National Cancer Institute (NCI)
Phase 2CCC
FLUDEOXYGLUCOSE
National Cancer Institute (NCI)
Phase 2CCC
Oxodotreotide
National Cancer Institute (NCI)
Phase 1CC
[212pb]vmt-alpha-net
National Cancer Institute (NCI)
Phase 1CC

Same molecule, other indications

Olaparib is also rated in:

breast carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
fallopian tube serous adenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →